Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389339 | 0.95 | F10 (0.58) | F10KMT2AHTR4CYP2D6CYP2C9 | |
| SCHEMBL13461288 | 0.93 | SLC6A5 (0.51) | F10KMT2AHTR4 | |
| SCHEMBL13881274 | 0.92 | F10 (0.60) | F10KMT2AHTR4MCHR1IGF1R | |
| SCHEMBL12893788 | 0.91 | HTR4 (0.48) | F10KMT2AHTR4MCHR1CYP2D6 | |
| SCHEMBL12894062 | 0.91 | HTR4 (0.48) | F10KMT2AHTR4MCHR1CYP2D6 | |
| SCHEMBL13881189 | 0.90 | KMT2A (0.57) | F10KMT2AHTR4CYP2D6CYP2C9 | |
| SCHEMBL736450 | 0.90 | KMT2A (0.57) | F10KMT2AHTR4CYP2D6CYP2C9 | |
| SCHEMBL13181455 | 0.90 | KMT2A (0.57) | F10KMT2AHTR4CYP2D6CYP2C9 | |
| SCHEMBL13457659 | 0.89 | HTR4 (0.52) | F10HTR4MCHR1ACHE | |
| SCHEMBL12893438 | 0.88 | HTR4 (0.52) | F10KMT2AHTR4MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |